Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC)
- Status
- TERMINATED
- Phase
- PHASE3
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
- Status
- WITHDRAWN
- Phase
- PHASE2
An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia
- Status
- COMPLETED
- Phase
- N/A
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of DF1001 in Patients With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- EARLY_PHASE1
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
- Status
- UNKNOWN
- Phase
- PHASE2
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread
- Status
- COMPLETED
- Phase
- PHASE1
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
- Status
- WITHDRAWN
- Phase
- PHASE1
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PVSRIPO in Combination With Nivolumab in Melanoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
- Status
- COMPLETED
- Phase
- PHASE2
Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
- Status
- TERMINATED
- Phase
- PHASE2